Novartis NVS · NYSE
$151.09 -3.32% (-$5.19)
Summary
71 / 100 · Bulios Score
What speaks for it
- Earnings per share grew by 31% a year over the last 3 years.
- Out of every 100 USD of revenue, 23 USD is left as net profit.
- It earns 14 USD a year on every 100 USD of invested capital.
- It bought back its own shares for $9.26B in the last fiscal year, 3.1% of its market value.
What to watch
- Earnings per share swing sharply from year to year.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Fairly pricedBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 23.3 USD for 1 USD of yearly profit. Over the last five years it was 17.0 USD on average.
Valuation in detailIs it growing?
Yes, fastRevenue (USD)
Diluted EPS (USD)
- Analyst estimate
Revenue grew by 1.9% a year over 5 years. Over the last 3 years it grew by 8.0% a year. For the next fiscal year analysts expect revenue to grow by 4.4%. Earnings per share grew by 31% a year over the last 3 years.
Growth in detailDoes it make money?
Very wellWhere 100 USD of revenue goes
- Cost of sales 26 USD
- Research and development 20 USD
- Sales and administration 24 USD
- Taxes and other 7.6 USD
- Net profit 23 USD
Net profit, industry median (Drug Manufacturers - General) 14 USD
Out of every 100 USD of revenue, 23 USD is left as net profit.
Profitability in detailIs it financially healthy?
MostlyRepaying all its debt would take 3.1 years of free cash flow. Its debt is larger than its cash.
Financial health in detailDoes it pay a dividend?
Moderate, stretched- Yield
- 3.03%
- Paid out of profit
- 71%
- Raised in a row
- 3 years
You receive $4.74 per share a year. The payout takes a large part of its profit or free cash flow.
Dividends in detailWhat do analysts expect?
Neutral- Buy 6
- Hold 17
- Sell 2
Today's price within the analysts' price targets
The average target of $146 is 3.4% below today's price. 24% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
Fiscal year 2022By product
- Top 20 products 74%
- Rest of portfolio 21%
- Total anti-infectives net sales 2.8%
- Anti Infectives sold under Sandoz name 1.8%
By region
- Other countries 40%
- UNITED STATES 35%
- GERMANY 8.5%
- CHINA 6.2%
- FRANCE 4.5%
- Other 6.3%
Top 20 products brings in 74% of revenue.
Segments in detail